Insmed (NASDAQ:INSM) Announces Earnings Results, Misses Expectations By $0.15 EPS

Insmed (NASDAQ:INSM) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15), Zacks reports. Insmed updated its FY 2025 guidance to EPS.

Insmed Stock Performance

Shares of INSM traded down $0.18 during trading hours on Thursday, hitting $83.65. The company’s stock had a trading volume of 694,495 shares, compared to its average volume of 1,874,655. The business has a 50 day simple moving average of $73.87 and a two-hundred day simple moving average of $73.45. Insmed has a 52-week low of $21.92 and a 52-week high of $83.99. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company has a market cap of $14.96 billion, a price-to-earnings ratio of -15.07 and a beta of 1.11.

Insider Activity at Insmed

In related news, insider Martina M.D. Flammer sold 3,344 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04. Following the sale, the insider now owns 102,766 shares of the company’s stock, valued at approximately $6,773,307.06. This represents a 3.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Sara Bonstein sold 13,302 shares of Insmed stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $80.00, for a total value of $1,064,160.00. Following the transaction, the chief financial officer now directly owns 142,204 shares of the company’s stock, valued at $11,376,320. The trade was a 8.55 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 495,135 shares of company stock worth $38,409,713. 4.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on INSM. Wells Fargo & Company increased their target price on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research note on Wednesday. Morgan Stanley lifted their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Guggenheim lifted their price target on Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Finally, Truist Financial restated a “buy” rating and issued a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.86.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.